Verification of GM2 Activator Protein for Potential Application as Lung Cancer Biomarker
Laddawan. Potprommanee1, Kongsak. Boonyapranai2, Padchanee. Sangthong1
, Busayamass. Chewaskulyong3, Shui-Tein. Chen4, and Lalida. Shank5
1.Department of Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand
2.Faculty of Medical Science, Nakhonratchasima College, Nakhonratchasima, Thailand
3.Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai, Thailand
4.Institute of Biological Chemistry, Academia Sinica and Institute of Biochemical Science, College of Life Science, National Taiwan University, Taipei, Taiwan
5.Department of Chemistry and Center for Innovation in Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand
2.Faculty of Medical Science, Nakhonratchasima College, Nakhonratchasima, Thailand
3.Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai, Thailand
4.Institute of Biological Chemistry, Academia Sinica and Institute of Biochemical Science, College of Life Science, National Taiwan University, Taipei, Taiwan
5.Department of Chemistry and Center for Innovation in Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand
Abstract—Lung cancer is the leading cause of cancer–related deaths worldwide. Finding effective biomarkers for early diagnosis would benefit available treatments. By 2-DE analysis, GM2 activator protein (GM2AP) was increased in urine samples of lung cancer patients. An increase of GM2AP level in urine samples of lung cancer patients were verified by Western blot analysis, using healthy donors as controls. Levels of urinary GM2AP in samples from the patients were significantly increased with 23-fold higher than that found in healthy controls. The increased level of GM2AP was also confirmed in serum samples of lung cancer patients. The levels of GM2AP were found with 14-fold in lung cancer patients compared to those from healthy controls. Multiple reaction monitoring (MRM) assay revealed that the concentration of urinary GM2AP in lung cancer patients were at 1.960, 1.334 and 9.303 μM/mL, whereas in the healthy controls was found at 1.082, 1.177 and 1.028 μM/mL. The concentration of the serum samples of lung cancer patients and healthy controls were found at 2.113, 1.284 and 1.375 μM/mL, whereas in healthy controls were found at 0.995, 0.953 and 0.768 μM/mL, respectively. Therefore, we suggest that GM2AP might serve as preliminary candidate biomarker of lung cancer.
Index Terms—GM2 activator protein, lung cancer, biomarker, 2-DE analysis, Western blot analysis, multiple reaction monitoring
Cite: Laddawan. Potprommanee, Kongsak. Boonyapranai, Padchanee. Sangthong, Busayamass. Chewaskulyong, Shui-Tein. Chen, and Lalida. Shank, "Verification of GM2 Activator Protein for Potential Application as Lung Cancer Biomarker," Journal of Medical and Bioengineering, Vol. 4, No. 4, pp. 280-287, August 2015. Doi: 10.12720/jomb.4.4.280-287
Index Terms—GM2 activator protein, lung cancer, biomarker, 2-DE analysis, Western blot analysis, multiple reaction monitoring
Cite: Laddawan. Potprommanee, Kongsak. Boonyapranai, Padchanee. Sangthong, Busayamass. Chewaskulyong, Shui-Tein. Chen, and Lalida. Shank, "Verification of GM2 Activator Protein for Potential Application as Lung Cancer Biomarker," Journal of Medical and Bioengineering, Vol. 4, No. 4, pp. 280-287, August 2015. Doi: 10.12720/jomb.4.4.280-287
Array